Sanofi's Shantha prepared to deliver 37M doses of long-delayed pediatric vaccine

Sanofi ($SNY) faced a long delay before its Indian affiliate, Shantha Biotechnics, finally came through with the launch of its low-cost pediatric pentavalent vaccine, Shan5. But now that it has, it says it's ready to deliver 37 million doses of the jab--and it's already begun, handing over 400,000 to aid immunization in Gwalior and Jabalpur. More from FierceVaccines

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.